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BRD7The androgen receptor (AR) is a ligand-dependent transcription factor that belongs to the family of nuclear
receptors, and its activity is regulated by numerous AR coregulators. AR plays an important role in prostate
development and cancer. In this study, we found that TRIM24/transcriptional intermediary factor 1α
(TIF1α), which is known as a ligand-dependent nuclear receptor co-regulator, interacts with AR and
enhances transcriptional activity of AR by dihydrotestosterone in prostate cancer cells. We showed that
TRIM24 functionally interacts with TIP60, which acts as a coactivator of AR and synergizes with TIP60 in the
transactivation of AR. We also showed that TRIM24 binds to bromodomain containing 7 (BRD7), which can
negatively regulate cell proliferation and growth. A luciferase assay indicated that BRD7 represses the AR
transactivation activity upregulated by TRIM24. These ﬁndings indicate that TRIM24 regulates AR-mediated
transcription in collaboration with TIP60 and BRD7.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Hormonal regulation of gene activity is mediated by nuclear
receptors acting as ligand-activated transcription factors. Ligand-
dependent activation of nuclear receptors requires intermediary
factors that interact with the C-terminal activating domain AF-2,
which is highly conserved in the nuclear receptor family [1]. The
androgen receptor (AR) is a member of the nuclear receptor family
and cooperates with various coregulators to modulate their target
genes for proper function. AR upregulates or downregulates target
gene expressions, depending on coactivators or corepressors [2].
Activities of AR and coregulators are regulated by posttranslational
modiﬁcations, such as methylation, phosphorylation, acetylation, and
ubiquitination [3–6]. Some of these coregulators contain E3 ligase
activity, and AR transcriptional activity requires proteasome activity
via regulation of AR nuclear translocation and interaction with
coregulators in prostate cancer cells [7].
Tripartite motif (TRIM) proteins are characterized by the presence
of a RING ﬁnger, one or two zinc-binding motifs named B-boxes, and
an associated coiled-coil region. Many TRIM proteins have been
reported to have a role in the ubiquitination process, and several TRIM
family members are involved in various cellular processes, such as
transcriptional regulation, cell growth, apoptosis, development, and+81 11 706 5169.
yama).
ll rights reserved.oncogenesis. Alterations of these might disrupt growth regulations
that lead to cancer formation [8].
TRIM24, one of the TRIM family proteins, has an N-terminal TRIM
domain with potential self-assembly properties [9,10], a nuclear
receptor interaction box (NR box or LxxLL motif), and a C-terminal
region containing a PHD ﬁnger and a bromodomain [11,12], two well-
conserved signature motifs widely distributed among nuclear
proteins known to function at the chromatin level [13–15]. The latter
two domains are also found in other transcriptional cofactors and
chromatin-remodeling proteins [16] and are likely to mediate
protein–protein interactions. TRIM24 associates with chromatin [17]
and the association is mediated by bromodomain–DNA and bromo-
domain–nucleosome interactions [18]. TRIM24 belongs to the
transcriptional intermediary factor 1 family that also includes TIF1β,
TIF1γ, and TIF1δ, all of which are believed to regulate chromatin
structure [12,16,19–21]. TRIM24 is one of the coregulators that has
been identiﬁed as a molecule interacting with retinoic acid receptor
(RAR) in a ligand-dependent fashion [11] and has also been found to
interact via a single LXXLL motif with the AF-2 transcriptional
activation domain of several nuclear receptors, including thyroid
(TR), vitamin D3 (VDR), and estrogen (ER) receptors other than RAR
[12,22]. TRIM24 likely modulates their transcriptional activity either
positively or negatively in a ligand-dependent fashion. TIF1β interacts
with heterochromatin-associated factors HP1α, HP1β and HP1γ to
promote silencing on euchromatic genes [23,24], and colocalization of
both TIF1β and HP1α/βwith centromeres is required for induction of
the parietal and visceral endoderm differentiation pathways [25,26].
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mediated gene silencing [27]. TRIM24 has also been demonstrated
to interact with HP1α, HP1β and HP1γ [12]. Furthermore, it has been
reported that TRIM24 is involved in modulating gene expression
during the ﬁrst wave of transcriptional activation in the mouse
embryo [28] and that TRIM24 acts in mice as a potent liver-speciﬁc
tumor suppressor by attenuating retinoic acid receptor α-mediated
transcription [29].
Bromodomain containing 7 (BRD7) is a bromodomain-containing
gene product that was identiﬁed from nasopharyngeal carcinoma
(NPC) cells by cDNA representational difference analysis. Expression
of BRD7 was decreased or lost in NPC biopsies and cell lines, but the
expression level was high in the normal nasopharyngeal epithelium
[30]. Moreover, overexpression of BRD7 inhibits NPC cell growth and
arrests the cells in G0/G1 phase by regulating transcription of some
important molecules involved in ras/MEK/ERK and Rb/E2F pathways
[31]. It has also been found that BRD7 can inhibit accumulation of
β-catenin in the nucleus and plays a negative role in the MEK/ERK
pathway [32]. It has been reported that BRD7 interacts with nuclear
transcription factor IRF2 [33] and forms a triple complex with
adenovirus nuclear protein E1B-AP5, thereby affecting the transcrip-
tional activity of E1B-AP5 [34].
In this study, we showed that TRIM24 acts as a coactivator of AR in
prostate cancer cells. Furthermore, we identiﬁed BRD7 as a novel
TRIM24-interacting protein by yeast two-hybrid screening and found
that BRD7 inhibits the transcriptional activity of AR upregulated by
TRIM24.
2. Materials and methods
2.1. Cell culture
Prostate cancer cell lines CWR22Rv1, LNCaP-FGC and PC3 were
provided by ATCC. CWR22Rv1 and LNCaP were cultured under an
atmosphere of 5% CO2 at 37°C in RPMI 1640 (Sigma) supplemented
with 10% fetal bovine serum (Invitrogen). PC3, HEK293T and COS7 cell
lines were cultured under the same conditions in DMEM (Sigma)
supplemented with 10% fetal bovine serum.
2.2. Cloning of cDNAs and plasmid construction
Mouse TRIM24 cDNA was ampliﬁed from a mouse T cell cDNA
library by PCR with BlendTaq (Takara). The ampliﬁed fragments did
not contain the DNA sequence corresponding to amino acids 10–111,
which encodes about 75% of a RING ﬁnger domain, and were utilized
as TRIM24(ΔRING). Full-length TRIM24 was constructed by using
the fragments ampliﬁed from a mouse testis cDNA library by PCR
with KOD-plus (Toyobo). They were subcloned into pSC-A (Strata-
gene) and sequenced. Mouse BRD7 cDNA was ampliﬁed by PCR
using pACT2-BRD7 isolated from yeast two-hybrid screening as a
template and the ampliﬁed fragments were subcloned into pBlue-
script II SK+ (Stratagene). TRIM24 and BRD7 cDNAs were subcloned
into p3xFLAG (Sigma) and pCGN-HA [35] for expression in
eukaryotic cells and into pBTM116 and pACT2 (Clontech) for a
yeast two-hybrid system. A deletion mutant of BRD7 cDNA contain-
ing amino acids 237–651 was subcloned from pCGN-HA-BRD7 by
digesting with EcoRI. AR and TIP60 cDNAs were kindly provided by
Dr. Sobue (Nagoya University) and Dr. Ikura (Tohoku University),
respectively.
2.3. Yeast two-hybrid screening
Complementary DNA encoding the full-length of mouse TRIM24
was fused in-frame to the nucleotide sequence for the LexA domain
(BD) in the yeast two-hybrid vector pBTM116. To screen for proteins
that interact with TRIM24, we transfected yeast strain L40 (Invitro-gen) stably expressing the corresponding pBTM116 vector with a
mouse brain cDNA library (Clontech).
2.4. Antibodies and reagents
The antibodies used were as follows: mouse monoclonal anti-HA
(HA.11/16B12, Covance), rabbit polyclonal anti-HA (Y11, Santa Cruz),
mouse monoclonal anti-FLAG (M2 or M5, Sigma), mouse monoclonal
anti-TRIM24 (Abnova), mouse monoclonal anti-AR (Santa Cruz),
rabbit polyclonal anti-BRD7 (Aviva) and mouse monoclonal anti-β-
actin (AC15, Sigma). Dihydrotestosterone (DHT), bicalutamide and
ﬂutamide were purchased from Sigma.
2.5. Transfection, immunoprecipitation, and immunoblot analysis
HEK293T cells were transfected by the calcium phosphate
method and lysed in a solution containing 50 mmol/L Tris–HCl
(pH 7.4), 150 mmol/L NaCl, 1% Nonidet P-40, leupeptin (10 μg/mL),
1 mmol/L phenylmethylsulfonyl ﬂuoride, 400 μmol/L Na3VO4,
400 μmol/L EDTA, 10 mmol/L NaF, and 10 mmol/L sodium
pyrophosphate. The cell lysates were centrifuged at 16,000g for
15 min at 4 °C, and the resulting supernatant was incubated with
antibodies for 2 h at 4 °C. Protein A-sepharose (Amersham Pharmacia
Biotech) that had been equilibrated with the same solution was
added to the mixture, which was then rotated for 1 h at 4 °C. The
resin was separated by centrifugation, washed ﬁve times with ice-
cold lysis buffer, and then boiled in SDS sample buffer. Immunoblot
analysis was performed with primary antibodies, horseradish
peroxidase-conjugated antibodies to mouse or rabbit IgG (1:10,000
dilution; Promega), and an enhanced chemiluminescence system
(Amersham Pharmacia).
2.6. Dual-luciferase assay
Cells were seeded in 24-well plates at 1×105 cells per well
(CWR22Rv1 and LNCaP) or 5×104 cells per well (PC3) and incubated
at 37 °C with 5% CO2 for 24 h. The mouse mammary tumor virus-
luciferase (MMTV-Luc) reporter plasmid and the pRL-TK Renilla
luciferase plasmid (Promega) were transfected with TRIM24 and/or
BRD7 expression vectors into CWR22Rv1, LNCaP or PC3 cells using
Fugene HD reagent (Roche). Transfected cells were incubated in
phenol-red free RPMI 1640 or DMEM (Invitrogen) supplementedwith
10% charcoal-treated fetal bovine serum (Equitech-Bio) for 24 h and
then incubated with DHT (10 nmol/L), bicalutamide (1 μmol/L) or
ﬂutamide (1 μmol/L) for 24 h, harvested, and assayed for luciferase
activity with a Dual-Luciferase Reporter Assay System (Promega). The
luminescence was quantiﬁed with a luminometer (Promega).
2.7. Pulse-chase analysis with cycloheximide
Transiently transfected HEK293T cells were cultured with cyclo-
heximide at the concentration of 50 μg/mL and then incubated for
various times. Cell lysates were then subjected to SDS-PAGE and
immunoblot analysis with antibodies to HA, β-actin and FLAG.
2.8. Immunoﬂuorescence staining
COS7 cells expressing FLAG-tagged TRIM24 (wild-type or ΔRING)
or HA-tagged BRD7 grown on a glass cover were ﬁxed for 10 min at
room temperature with 2% formaldehyde in PBS and then incubated
for 1 h at room temperature with primary antibody to FLAG or HA in
PBS containing 0.1% bovine serum albumin and 0.1% saponin. They
were then incubated with Alexa488-labeled goat polyclonal antibody
to mouse immunoglobulin or Alexa546-labeled goat polyclonal
antibody to rabbit immunoglobulin (Molecular Probes) at a dilution
of 1:1,000. The cells were covered with a drop of VECTASHIELD
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Olympus) attached to an Olympus BX51 microscope.
2.9. Statistical analysis
The unpaired Student's t test was used to determine the statistical
signiﬁcance of experimental data.
3. Results
3.1. TRIM24 interacts with AR in vivo
Since it has been reported that TRIM24 is a transcriptional
regulator of several nuclear receptors, we hypothesized that TRIM24
is involved also in the AR signaling pathway in prostate cancer cells.
We checked the expression levels of TRIM24 and AR in prostate cancer
cell lines including CWR22Rv1, LNCaP and PC3. Immunoblot analysis
showed that these prostate cancer cell lines express TRIM24 and that
CWR22Rv1 and LNCaP abundantly express AR, whereas PC3 expresses
AR at barely detectable levels [36] (Fig. 1A). It has already been
reported that CWR22Rv1 expresses a full-length AR isoform of
114 kDa containing an in-frame tandem duplication of exon 3 with
H874Y mutation in the ligand-binding domain and a carboxy-
terminally truncated form of 75–80 kDa that lacks a ligand-bindingFig. 1. TRIM24 physically interacts with AR in vivo. (A) Expression of endogenous
TRIM24 and AR in several prostate cancer cell lines. Whole cell lysates from prostate
cancer cell lines were immunoblotted (IB) with an antibody to TRIM24, AR or β-actin.
(B) An in vivo binding assay between TRIM24 and AR. FLAG-tagged TRIM24 and HA-
tagged AR expression vectors were transfected into HEK293T cells. Whole cell lysates
(WCL) were immunoprecipitated (IP) with anti-FLAG antibody and immunoblotted
with an antibody to HA or FLAG. (C) Interaction between endogenous TRIM24 and
AR in prostate cancer cells. CWR22Rv1 cells were treated with dihydrotestosterone
(DHT) and lysed. Then WCLs were immunoprecipitated with anti-AR antibody and
immunoblotted with an antibody to TRIM24 or AR.domain, and it has been shown that LNCaP expresses a full-length AR
but that AR in LNCaP contains one point mutation (T877A) [37–39].
To determine whether TRIM24 physically interacts with AR in vivo,
expression vectors encoding FLAG-tagged TRIM24 and HA-tagged AR
were transfected into HEK293T cells. The cell lysates were subjected
to immunoprecipitation with anti-FLAG antibody, and the resulting
precipitates were subjected to immunoblot analysis with antibodies
to HA and FLAG. We found that TRIM24 speciﬁcally interacts with AR
(Fig. 1B). We also veriﬁed interaction between endogenous TRIM24
and AR in CWR22Rv1 cells with dihydrotestosterone (DHT) treatment
by immunoprecipitation with anti-AR antibody (Fig. 1C).
3.2. TRIM24 enhances AR-mediated transcriptional activity
To examine whether TRIM24 affects AR-mediated transcriptional
activity, we performed a luciferase reporter assay using an MMTV
promoter-driven luciferase construct (MMTV-Luc) in CWR22Rv1
cells. FLAG-tagged TRIM24 expression vector and MMTV-Luc were
transfected into CWR22Rv1 cells, and luciferase activity was mea-
sured with or without DHT. The luciferase assays showed that TRIM24
enhances androgen-dependent AR-mediated transcriptional activity
in a dose-dependent fashion (Fig. 2A). We performed immunoblot
analysis using anti-FLAG and anti-TRIM24 antibodies to compare the
expression levels of endogenous TRIM24 and transfected FLAG-
TRIM24, and the results suggested that overexpressed TRIM24 causes
an increase in transcriptional activity (Fig. 2B).
It has been reported that PC3 cells transfected with AR can be used
for AR-mediated transactivation assay [40–43]. To determine whether
the effect of TRIM24 depends on the expression of AR, we performed a
luciferase reporter assay with PC3 cells which do not express AR
(Fig. 1A). Androgen-dependent AR-mediated transcriptional activity
was not increased in PC3 cells, regardless of transfection of TRIM24.
However, PC3 cells that were transiently transfected with an
expression vector encoding AR showed androgen-dependent AR-
mediated transcriptional activity and TRIM24 further enhanced the
activity. These ﬁndings showed that the expression of AR is required
for androgen-dependent transcriptional activation via TRIM24
(Fig. 2C).
3.3. TRIM24 lacking a RING ﬁnger domain also enhances AR-mediated
transcriptional activity
To investigate the role of a RING ﬁnger domain of TRIM24 in AR-
mediated transcriptional activity, we used a deletion mutant lacking a
RING ﬁnger domain of TRIM24 (TRIM24(ΔRING)) for a luciferase
reporter assay (Fig. 3A). The TRIM24(ΔRING) mutant also enhanced
androgen-dependent AR-mediated transcriptional activity in a dose-
dependent fashion (Fig. 3B), but its effect was slightly weaker than
that of wild-type TRIM24 (Fig. 3C), suggesting that the RING domain is
partially important for AR-mediated transcription by TRIM24.
To conﬁrm the physiologic role of TRIM24 in AR-mediated
transcription, we used RNAi to down-regulate endogenous TRIM24
in CWR22Rv1 cells. Short interference RNAs (siRNA) targeting
TRIM24 were introduced into CWR22Rv1 cells using a retroviral
infection system. RNAi treatment resulted in signiﬁcant silencing of
TRIM24 at the protein level in CWR22Rv1 cells (Fig. S1A). To examine
the effect of the depletion of TRIM24 on AR-mediated transcriptional
activity, we performed a luciferase reporter assay in CWR22Rv1 cells
transfected with TRIM24 siRNA. Down-regulation of TRIM24 caused a
slight decrease in androgen-dependent AR-mediated transcriptional
activity but did not show a statistically signiﬁcant effect (Fig. S1B).
It has been reported that antiandrogen reagents inhibit AR-
mediated transcriptional activity induced by androgen [44–46] and
that the AR-coactivator CBP enhances AR-mediated transcriptional
activity in the presence of the antiandrogens hydroxyﬂutamide and
bicalutamide [47]. To examine whether TRIM24 acts as an agonist for
Fig. 2. TRIM24 enhances AR-mediated transcriptional activity in prostate cancer cells.
(A) TRIM24 enhances AR-mediated transcriptional activity in CWR22Rv1 cells. MMTV
luciferase reporter vector (MMTV-Luc) and various amounts of FLAG-tagged TRIM24
expression vector were transfected into CWR22Rv1 cells. Transfected cells were
incubated in culture medium containing 10% charcoal-treated fetal bovine serum for
24 h and then incubated with or without DHT (10 nmol/L) for 24 h. The cells were then
harvested and assayed for luciferase activity. Data are means±SD of values from three
independent experiments. P values for the indicated comparisons were determined by
Student's t test. (B) A comparison of the protein levels of endogenous and transfected
TRIM24. Whole cell lysates used in the experiment for which results are shown in
Fig. 1A were immunoblotted with an antibody to TRIM24, FLAG or β-actin. (C) AR-
dependent transcriptional activation of TRIM24. MMTV-Luc and TRIM24 expression
vectors were transfected into PC3 cells with or without AR expression vector.
Transfected cells were incubated in culture medium containing 10% charcoal-treated
fetal bovine serum for 24 h and then incubatedwithorwithoutDHT (10nmol/L) for 24 h.
The cells were then harvested and assayed for luciferase activity. Data are means±SD of
values from three independent experiments. P values for the indicated comparisonswere
determined by Student's t test.
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antiandrogens, we performed a luciferase reporter assay using the
antiandrogens bicalutamide and ﬂutamide. Luciferase reporter assays
showed that both drugs affected androgen-dependent transcriptionalactivity but partially suppressed the transcriptional activation by
TRIM24. However, neither bicalutamide nor ﬂutamide acted as an
agonist in the presence of TRIM24 (Fig. 3D and E).
3.4. TRIM24 cooperates with TIP60 to enhance AR-mediated
transcriptional activity
Previous studies by us and others have shown that AR and
coregulators are regulated by histone acetyltransferases, such as
TIP60, to enhance AR-mediated transcriptional activity [5,48].
Therefore, we hypothesized that TRIM24 physically or functionally
interacts with TIP60. To determine whether TRIM24 physically
interacts with TIP60, expression vectors encoding FLAG-tagged
TRIM24 and HA-tagged TIP60 were transfected into HEK293T cells.
The cell lysates were subjected to immunoprecipitation with anti-HA
antibody, and then immunoblot analysis was performed with an
antibody to FLAG or HA. An in vivo binding assay showed that TRIM24
speciﬁcally interacts with TIP60 (Fig. 4A). To determine whether
TRIM24 functionally interacts with TIP60, we performed an AR
transactivation assay. CWR22Rv1 cells were cotransfected with
expression vectors encoding TIP60 and/or TRIM24 with MMTV-Luc
as a reporter and treated with or without DHT, and then luciferase
reporter assays were performed. TIP60 and TRIM24 individually
enhanced AR-mediated transactivation by DHT. Most importantly, the
combination of TIP60 and TRIM24 further enhanced AR-mediated
transcriptional activity (Fig. 4B). These ﬁndings suggest that TRIM24
cooperates with the coactivator TIP60 for AR-mediated
transactivation.
3.5. TRIM24 interacts with BRD7
To identify novel proteins that interact with TRIM24, we
performed yeast two-hybrid screening from a mouse brain cDNA
library by using full-length TRIM24 as bait. Twenty-nine positive
clones were isolated on Leu-Trp-His-deﬁcient medium from 6.1×105
transformants. One of the positive clones was identiﬁed as bromodo-
main containing 7 (BRD7). We tested whether TRIM24 physically
interacts with BRD7 in vivo. We expressed FLAG-tagged TRIM24 and
HA-tagged BRD7 in HEK293T cells. Cell lysates were subjected to
immunoprecipitation with anti-HA antibody, and the resulting
precipitates were subjected to immunoblot analysis with an antibody
to FLAG or HA. An in vivo binding assay showed that FLAG-tagged
TRIM24 speciﬁcally interacts with HA-tagged BRD7 (Fig. 5A). Next, to
examine whether a RING ﬁnger domain of TRIM24 and a bromodo-
main of BRD7 are required for the interaction between TRIM24 and
BRD7, we constructed a BRD7 mutant lacking a bromodomain (BRD7
(ΔBRD)) (Fig. 5B). An in vivo binding assay clariﬁed that TRIM24
(ΔRING) interacts with BRD7 (Fig. 5C) and that BRD7(ΔBRD) interacts
with TRIM24 (Fig. 5D), indicating that a RING ﬁnger domain of
TRIM24 and a bromodomain of BRD7 are dispensable for the
interaction between TRIM24 and BRD7.
3.6. TRIM24 colocalizes with BRD7 but does not accelerate degradation
of BRD7
Next, we performed immunoﬂuorescence staining to determine
the subcellular localization of TRIM24 (WT or ΔRING) and BRD7. COS7
cells were transfected with expression vectors encoding FLAG-tagged
TRIM24 (WT or ΔRING) or HA-tagged BRD7 and then ﬁxed and
stained with antibodies to FLAG or HA with Hoechst33258 to reveal
the subcellular distribution of FLAG-tagged TRIM24 (WT or ΔRING)
(green), HA-tagged BRD7 (red), and nuclei (blue). Immunoﬂuores-
cence staining revealed that both FLAG-tagged TRIM24(WT) and HA-
tagged BRD7 showed a predominantly nuclear localization pattern,
whereas TRIM24(ΔRING) showed a predominantly cytosolic locali-
zation pattern (Fig. 6A).
Fig. 3. TRIM24 lacking a RING ﬁnger domain also enhances AR-mediated transcriptional activity. (A) Schematic representation of wild-type (WT) TRIM24 and TRIM24(ΔRING).
TRIM24 has a RING ﬁnger, two B-boxes, a coiled-coil region, a PHD domain and a bromodomain. (B) TRIM24(ΔRING) enhances AR-mediated transcriptional activity. MMTV-Luc and
various amounts of TRIM24(ΔRING) expression vector were transfected into CWR22Rv1 cells. Transfected cells were incubated in culture medium containing 10% charcoal-treated
fetal bovine serum for 24 h and then incubated with or without DHT (10 nmol/L) for 24 h. The cells were then harvested and assayed for luciferase activity. Data are means±SD of
values from three independent experiments. P values for the indicated comparisons were determined by Student's t test. (C) TRIM24(ΔRING) retains partial activity compared with
that of wild-type TRIM24. MMTV-Luc and TRIM24 (WT or ΔRING) expression vectors were transfected into CWR22Rv1 cells. Transfected cells were incubated in culture medium
containing 10% charcoal-treated fetal bovine serum for 24 h and then incubated with or without DHT (10 nmol/L) for 24 h. The cells were then harvested and assayed for luciferase
activity. Data are means±SD of values from three independent experiments. P values for the indicated comparisons were determined by Student's t test. (D and E) Antiandrogens
suppress AR-mediated transcriptional activity via TRIM24. MMTV-Luc and TRIM24(WT) expression vectors were transfected into CWR22Rv1 cells. Transfected cells were incubated
in culture medium containing 10% charcoal-treated fetal bovine serum for 24 h and then incubated with or without DHT (1 or 10 nmol/L), bicalutamide (1 μmol/L), and ﬂutamide
(1 μmol/L) for 24 h. The cells were then harvested and assayed for luciferase activity. Data are means±SD of values from three independent experiments. P values for the indicated
comparisons were determined by Student's t test.
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via its RING-ﬁnger domain [49], we could not ﬁnd enhanced
ubiquitination of BRD7 by TRIM24 (data not shown). We also
performed pulse-chase analysis to determine whether TRIM24 affects
the stability of BRD7. Pulse-chase analysis revealed that overexpres-
sion of TRIM24 does not accelerate the degradation of BRD7 (Fig. 6B
and C).3.7. Expression patterns of TRIM24 and BRD7 in various cell lines
To study the expression proﬁles of TRIM24 and BRD7, we compared
the protein levels of TRIM24 and BRD7 in various human cell lines from
different origins: prostate cancer cell lines CWR22Rv1, LNCaP and PC3,
acute myeloid leukemia cell lines KG-1, HL-60, NKM-1, J111, HEL,
KMOE-2 and CMK, chronic myeloid leukemia cell line K562, T cell
Fig. 4. TRIM24 cooperates with TIP60 to enhance AR-mediated transactivation. (A)
Physical interaction between TRIM24 and TIP60. Expression vectors encoding FLAG-
tagged TRIM24 and HA-tagged TIP60 were transfected into HEK293T cells as indicated.
After 24 h, cells were lysed and subjected to immunoprecipitation (IP) with anti-HA
antibody followed by immunoblotting (IB) with an antibody to FLAG or HA. Whole cell
lysates (WCL) were also subjected to immunoblotting to conﬁrm the expressions of
FLAG-tagged TRIM24 and HA-tagged TIP60. (B) TRIM24 cooperates with TIP60 to
enhance AR-mediated transactivation. CWR22Rv1 cells were cotransfected with
expression vectors encoding TIP60 and TRIM24 with MMTV-Luc as a reporter.
Transfected cells were incubated in culture medium containing 10% charcoal-treated
fetal bovine serum for 24 h and then incubatedwithorwithoutDHT (10nmol/L) for 24 h.
The cells were then harvested and assayed for luciferase activity. Data are means±SD of
values from three independent experiments. P values for the indicated comparisonswere
determined by Student's t test.
Fig. 5. TRIM24 interacts with BRD7. (A) An in vivo binding assay between TRIM24 and BRD
HEK293T cells. Whole cell lysates (WCL) were immunoprecipitated (IP) with anti-HA a
representation of wild-type (WT) BRD7 and BRD7(ΔBRD). BRD7 has a bromodomain. (C, D)
interaction between TRIM24 and BRD7. HEK293T cells were transfected with expression ve
HA-tagged BRD7(WT) or HA-tagged BRD7(ΔBRD), immunoprecipitated with anti-HA antib
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epithelial carcinoma cell line HeLa, and hepatocellular carcinoma cell
line HepG2 (Fig. 7). Immunoblot analysis using several cell lines
showed various expression patterns of TRIM24 and BRD7.
3.8. BRD7 represses AR-mediated transcriptional activity upregulated by
TRIM24
To examine whether BRD7 functionally affects AR-mediated
transcription in CWR22Rv1 cells, we performed a luciferase reporter
assay. BRD7 expression vector and MMTV-Luc were transfected into
CWR22Rv1 cells, and luciferase activity was measured with or
without DHT (Fig. 8A). The luciferase assays showed that BRD7
represses androgen-dependent transcriptional activity in a dose-
dependent fashion.
We also examined whether BRD7 modulates the effect of TRIM24
in the AR signaling pathway. CWR22Rv1 cells were cotransfected with
expression vectors encoding BRD7 and/or TRIM24 with MMTV-Luc as
a reporter and treatedwith or without DHT, and then luciferase assays
were performed. TRIM24 enhanced AR-mediated transactivation by
DHT. However, AR-mediated transcriptional activity by the combina-
tion of TRIM24 and BRD7wasmuch less than that by TRIM24 (Fig. 8B).
These ﬁndings suggest that BRD7 represses AR-mediated transcrip-
tional activity by TRIM24.
4. Discussion
AR signaling has key roles in the development and progression of
prostate cancer. Like other steroid receptors, the activity of AR is
regulated by a series of cofactors that either enhance or suppress AR-
mediated gene transcription [50]. It has been shown that TRIM24 has
various functions, including activation of AF-2 of nuclear receptors
such as RARα [11]. Since AR is also a ligand-dependent nuclear
receptor, TRIM24 may promote modiﬁcation of chromatin and
formation of a bridge between the DNA-bound nuclear receptor and
the basal transcriptional machinery recruiting or stabilizing the
chromatin remodeling proteins to the nuclear receptor target gene.
Moreover, it has been reported that TRIM24 is a phosphoprotein that7. FLAG-tagged TRIM24 and HA-tagged BRD7 expression vectors were transfected into
ntibody and immunoblotted (IB) with an antibody to FLAG or HA. (B) Schematic
A RING ﬁnger domain of TRIM24 and a bromodomain of BRD7 are not required for the
ctors encoding either FLAG-tagged TRIM24(WT) or FLAG-tagged TRIM24(ΔRING) and
ody, and immunoblotted with an antibody to FLAG or HA.
Fig. 6. Colocalization of TRIM24 and BRD7. (A) Localization of TRIM24 and BRD7 determined by immunoﬂuorescence analysis. COS7 cells were transfected with an expression vector
encoding FLAG-tagged TRIM24(WT), FLAG-tagged TRIM24(ΔRING) or HA-tagged BRD7. After 48 h, the cells were ﬁxed and stained with antibodies to FLAG or HA as well as
Hoechst33258 to reveal the subcellular distribution of FLAG-tagged TRIM24 (WT or ΔRING) (green), HA-tagged BRD7 (red), and nuclei (blue). Micrographs were obtained at
400×magniﬁcation (Scale bars, 20 μm). (B) Pulse-chase analysis of BRD7 with TRIM24. HEK293T cells were transfected with expression vectors encoding HA-tagged BRD7 and
FLAG-tagged TRIM24 or an empty vector (Mock). After 48 h, the cells were cultured in the presence of cycloheximide (50 μg/mL) for the indicated times. Cell lysates were then
subjected to immunoblot (IB) analysis with anti-HA, anti-β-actin or anti-FLAG antibody. (C) Intensity of the HA-BRD7 bands in panel B was normalized by that of the corresponding
β-actin bands and then expressed as a percentage of the normalized value at the beginning of the chase period. Data are means±SD of values from three independent experiments.
Fig. 7. Expression of TRIM24 and BRD7 in various cell lines. Cell lysates from prostate
cancer cell lines CWR22Rv1, LNCaP and PC3, acute myeloid leukemia cell lines KG-1,
HL-60, NKM-1, J111, HEL, KMOE-2 and CMK, chronic myeloid leukemia cell line K562, T
cell leukemia cell line Jurkat, embryonic kidney cell line HEK293T, uterine epithelial
carcinoma cell line HeLa, and hepatocellular carcinoma cell line HepG2 were subjected
to immunoblot (IB) analysis with anti-TRIM24, anti-BRD7 or anti-β-actin antibody.
1834 M. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1828–1836undergoes ligand-dependent hyperphosphorylation upon nuclear
receptor binding in vivo and that it also has a kinase activity that
can phosphorylate basal transcription factors (TFIIEα, TAFII28, and
TAFII55) in vitro [51]. However, the speciﬁc molecular mechanism of
TRIM24 as a coactivator and the relation to other coactivators
involved in transcriptional activation of endogenous genes remain
to be determined.
In this study, we showed that TRIM24 acts as a coactivator of AR in
prostate cancer cells. We found that TRIM24 physically interacts with
AR and enhances androgen-dependent AR-mediated transcriptional
activity in a dose-dependent fashion. TRIM24 lacking a RING ﬁnger
domain also has an activity for AR-mediated transcription, but its
activity is weaker than that of wild-type TRIM24. The difference in
Fig. 8. BRD7 represses AR-mediated transcriptional activity. (A) MMTV-Luc and various
amounts of BRD7 expression vector were transfected into CWR22Rv1 cells. Transfected
cells were incubated in culture medium containing 10% charcoal-treated fetal bovine
serum for 24 h and then incubated with or without DHT (10 nmol/L) for 24 h. The cells
were then harvested and assayed for luciferase activity. Data are means±SD of values
from three independent experiments. P values for the indicated comparisons were
determined by Student's t test. (B) BRD7 and/or TRIM24 expression vectors with
MMTV-Luc were transfected into CWR22Rv1 cells. Transfected cells were incubated in
culture medium containing 10% charcoal-treated fetal bovine serum for 24 h and then
incubated with or without DHT (10 nmol/L) for 24 h. The cells were then harvested
and assayed for luciferase activity. Data are means±SD of values from three
independent experiments. P values for the indicated comparisons were determined
by Student's t test.
1835M. Kikuchi et al. / Biochimica et Biophysica Acta 1793 (2009) 1828–1836subcellular localization likely causes the attenuation of transcriptional
activity by deletion of a RING ﬁnger domain: wild-type TRIM24
predominantly localizes in the nucleus, whereas TRIM24(ΔRING)
localizes also in the cytosol. A previous study showed that TRIM24
does not function as a coactivator by itself but only functions in
cooperation with GRIP1 and CARM1 in AR transcriptional activity
induced by DHT in the monkey kidney epithelial cell line CV-1 [16].
However, we showed that TRIM24 enhances transcriptional activity of
AR by DHT alone in the prostate cancer cell line CWR22Rv1. This
discrepancy may be due to the differences between the AR signaling
pathways in a kidney epithelial cell line and a prostate cancer cell line.
Otherwise, CWR22Rv1 cells may endogenously express GRIP1 and
CARM1.
It has been reported that TIP60 is crucial for AR-mediated
transactivation [52,53]. We also showed that TRIM24 physically
interacts with TIP60 and that TRIM24 cooperates with TIP60 for AR-
mediated transactivation. We previously have reported that TRIM68,
another TRIM family protein, enhances AR-mediated transactivation
in collaboration with TIP60 [54], suggesting that nuclear TRIM family
proteins other than TRIM68 and TRIM24 function as regulators for
transcription. In other nuclear receptor signaling, TRIM25/EFP has an
activity to enhance estrogen-dependent ER-mediated transcription
[55]. Therefore, it is likely that TRIM family proteins have important
roles in regulations of the transcriptional activity by nuclear receptors.
BRD7 plays a critical role in cellular growth, cell cycle progression,
and signal-dependent gene expression. A previous study has shown
that BRD7 plays a role in transcriptional regulation by binding to
acetylated histone H3, and thereby chromatin remodeling for
transcription is regulated by BRD7 [56]. We showed that BRD7
interacts with TRIM24 in this study. We compared the protein levels
of TRIM24 and BRD7 in various human cell lines from different origins
and found their expression patterns varied. Since it is important to
clarify the relation between TRIM24 and BRD7, we should further
analyze the expression proﬁles of TRIM24 and BRD7 using various
cancer tissues or developing tissues. More interestingly, TRIM24 did
not enhance ubiquitination of BRD7 (data not shown) or acceleratethe degradation of BRD7. However, BRD7 repressed AR-mediated
transcriptional activity upregulated by TRIM24. The molecular
mechanism of inhibition of TRIM24-mediated transcription by BRD7
remains to be determined. Future studies aimed at elucidation of the
relation between TRIM24 and BRD7 should be helpful for establishing
novel therapeutic tools for advanced hormone refractory and
metastatic prostate cancer.
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